A UK investment company was considering leading an investment round in a UK-based platform technology company utilizing induced pluripotent stem cells (iPSCs) in disease models as R&D tools. Alacrita was commissioned to undertake a high-level due diligence assessment of the technology, particularly considering the marketing position and competitive landscape.
Alacrita’s consulting team evaluated all relevant information of the target company and its technology. Using our market intelligence sources and networks our we evaluated: 1) the market positioning of the technology, considering current levels of market acceptance in drug discovery; 2) the competitive strengths of the technology and key competitive threats, notably from other emerging cell model technologies; 3) the extent to which the platform was technically differentiated from others in the field. Our findings were summarized in a detailed analysis report for the client, with important risk areas flagged and ranked.
Alacrita's due diligence consultants have been a trusted source of pharma and biotech DD for over 15 years, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise industry expertise required to be thorough, complete and accurate.